Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Long COVID
Interventions: Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: Douglas D. Fraser; Other
Eligibility: 18 Years to 65 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Fatty Liver
Interventions: fenofibrate, pioglitazone, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Heart Failure
Interventions: LOVAZA (Omega-3), Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection
Interventions: ICD/pacemaker pocket revision; Procedure
Lead sponsor: Dhanunjaya Lakkireddy, MD, FACC; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy
Interventions: FXR 450, placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Migraine, Acute Treatment of Migraine
Interventions: Rimegepant, Placebo, Sumatriptan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more

Conditions: Healthy
Interventions: Minocycline 100mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chapell Hill, North Carolina

Conditions: Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions: Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 12
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more

Conditions: Fontan Palliation
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dermatomyositis
Interventions: JBT-101, Placebo; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cocaine-Related Disorders
Interventions: N-Acetylcysteine, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: GLY-200, Placebo; Drug
Lead sponsor: Glyscend, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions: IMR-687, Placebo Oral Capsule; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Stress, Anxiety, Depression
Interventions: Non-Deceptive Placebo; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Anxiety Disorders, Mood Disorders, Insomnia, Nightmares
Interventions: Behavioral Sleep Intervention, Prazosin, Placebo; Behavioral · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Women With Breast Implants With and Without Self-reported Systemic Symptoms, Women Undergoing an Elective Mastopexy (Breast Lift) or Small Reduction
Interventions: Surgical collection of biospecimens; Procedure
Lead sponsor: Glicksman, Caroline, M.D.; Individual
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 150 participants
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sea Girt, New Jersey

Conditions: Diabetes
Interventions: Saxagliptin, Glyburide, Placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 54
States / cities: Jonesboro, Arkansas • Searcy, Arkansas • Alhambra, California + 49 more

Conditions: Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure
Interventions: Equol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: IXAZOMIB, Dexamethasone, Melphalan, Cyclophosphamide, Thalidomide, Lenalidomide; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Fabry Disease
Interventions: migalastat HCl 150 mg; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia

Conditions: Hepatitis C
Interventions: ABT-072; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Drug Drug Interaction (DDI)
Interventions: BMS-984923, Midazolam, Caffeine, dextromethorphan; Drug
Lead sponsor: Allyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

MAKE IT CLEAN, Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study

Study Evaluating the Safety of FXR-450 in Healthy Subjects

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

The Efficacy of Doxazosin for Cocaine Users

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

A Study of IMR-687 in Healthy Adult Volunteers

Effects of Open-label Placebos on COVID-related Psychological Health

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

Systemic Symptoms: Biospecimen Analysis Study

A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

Equol and Vascular Function in Women With Chronic Kidney Disease

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates